Original paper
An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation
Abstract
Increasing evidence suggests that signaling through the prolactin/prolactin receptor axis is important for stimulation the growth of many cancers including glioblastoma multiforme, breast and ovarian carcinoma. Efficient inhibitors of signaling have previously been developed but their applicability as cancer drugs is limited by the short in vivo half-life. In this study, we show that a fusion protein, consisting of the prolactin receptor...
Paper Details
Title
An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation
Published Date
May 7, 2019
Journal
Volume
14
Issue
5
Pages
e0215831 - e0215831
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History